Trials / Completed
CompletedNCT05361005
Tolerability and Safety of BDB-001 Injection in Healthy Subjects
A Phase Ic Single Center, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation and Multiple Dose Study to Evaluate the Tolerability and Pharmacokinetics of BDB-001 Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A clinical study to evaluate the tolerability, PK and PD characteristics of BDB-001 Injection in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BDB-001 injection | Intravenous injection |
| DRUG | Placebo | Intravenous injection |
Timeline
- Start date
- 2020-03-12
- Primary completion
- 2020-05-08
- Completion
- 2020-05-08
- First posted
- 2022-05-04
- Last updated
- 2022-05-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05361005. Inclusion in this directory is not an endorsement.